"Guanylate Cyclase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme that catalyzes the conversion of GTP to 3',5'-cyclic GMP and pyrophosphate. It also acts on ITP and dGTP. (From Enzyme Nomenclature, 1992) EC 4.6.1.2.
| Descriptor ID |
D006162
|
| MeSH Number(s) |
D08.811.520.650.600 D12.644.360.350 D12.776.476.350
|
| Concept/Terms |
Guanylate Cyclase- Guanylate Cyclase
- Cyclase, Guanylate
- Guanyl Cyclase
- Cyclase, Guanyl
- Guanylyl Cyclase
- Cyclase, Guanylyl
- Inosinate Cyclase
- Cyclase, Inosinate
- Deoxyguanylate Cyclase
- Cyclase, Deoxyguanylate
|
Below are MeSH descriptors whose meaning is more general than "Guanylate Cyclase".
Below are MeSH descriptors whose meaning is more specific than "Guanylate Cyclase".
This graph shows the total number of publications written about "Guanylate Cyclase" by people in this website by year, and whether "Guanylate Cyclase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 2 | 0 | 2 |
| 1995 | 2 | 0 | 2 |
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 4 | 0 | 4 |
| 2003 | 0 | 4 | 4 |
| 2004 | 3 | 1 | 4 |
| 2005 | 1 | 1 | 2 |
| 2006 | 0 | 2 | 2 |
| 2007 | 1 | 1 | 2 |
| 2008 | 1 | 4 | 5 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 3 | 1 | 4 |
| 2012 | 2 | 1 | 3 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 2 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 2 | 1 | 3 |
| 2018 | 1 | 0 | 1 |
| 2021 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Guanylate Cyclase" by people in Profiles.
-
Pityriasis Rubra Pilaris: An Updated Review of Clinical Presentation, Etiopathogenesis, and Treatment Options. Am J Clin Dermatol. 2024 Mar; 25(2):243-259.
-
Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial. Cancer Med. 2022 01; 11(1):61-73.
-
Resistance Mutations to BTK Inhibitors Originate From the NF-?B but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway. Front Immunol. 2021; 12:689472.
-
Gene Therapy Rescues Retinal Degeneration in Receptor Expression-Enhancing Protein 6 Mutant Mice. Hum Gene Ther. 2019 03; 30(3):302-315.
-
Hypomorphic caspase activation and recruitment domain 11 (CARD11) mutations associated with diverse immunologic phenotypes with or without atopic disease. J Allergy Clin Immunol. 2019 04; 143(4):1482-1495.
-
Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. Blood. 2018 01 11; 131(2):182-190.
-
Structural and Functional Impacts of ER Coactivator Sequential Recruitment. Mol Cell. 2017 Sep 07; 67(5):733-743.e4.
-
Combined immunodeficiency and atopy caused by a dominant negative mutation in caspase activation and recruitment domain family member 11 (CARD11). J Allergy Clin Immunol. 2018 05; 141(5):1818-1830.e2.
-
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Discov. 2017 09; 7(9):1018-1029.
-
Mechanistic characterization of nitrite-mediated neuroprotection after experimental cardiac arrest. J Neurochem. 2016 11; 139(3):419-431.